The Clinical Utility of Ki-67 in Assessing Tumor Biology and Aggressiveness in Patients with Appendiceal Carcinoids

Eric Liu, MD 1, Dana A. Telem, MD 1, John Hwang, BA 1, Richard R. P. Warner, MD 2, Steven H. Dikman, MD 3, and Celia M. Divino, MD, FACS 1

Department of Surgery 1, Department of Internal Medicine, Section of Gastroenterology 2, and Department of Pathology 3, Mount Sinai School of Medicine, New York, NY 10029

Purpose: To elucidate the correlation of Ki-67, a growth fraction marker of cell proliferation, with tumor biology and survival in patients with appendiceal carcinoid tumors.

Method: A retrospective chart review was conducted on 45 patients with appendiceal carcinoid tumors who underwent operative intervention from 1991 - 2008. MIB-1, a monoclonal antibody of Ki-67 measuring its expression, was used to determine cell proliferation and correlated with clinical and histological parameters. MIB-1 index was based on the WHO (world health organization) classification.

Result: Of the 45 patients, 28 had tumors <2cm; 8 >2cm; and 9 with unspecified tumor size. No significant difference was demonstrated in MIB-1 index between patients with tumors <2cm vs. >2cm: MIB-1<2% (71% vs. 63%; p=0.146), MIB-1 2-15% (14% vs. 13%; p=0.086) and MIB-1>15% (14% vs. 25%; p=0.356), respectively.

Eleven patients had metastatic disease on presentation: 7 had MIB-1 index <2%, 2 had index 2-15% and 2 with index >15%. No significant correlation between MIB index and metastasis was demonstrated (p=0.774).

Median follow-up was 32 months (range 6-122 months) with a 53.3% follow-up rate. Of the 24 patients with follow up, there were 5 mortalities and 2 recurrences. No significant difference in survival was demonstrated by MIB-1 index.

Conclusion: This study demonstrated no correlation between Ki-67 and tumor size or presentation with metastasis. While no significant difference was demonstrated in survival rate with increasing MIB-1 index, sample size and duration of follow-up limits definitive conclusions and further investigation is required. As prognostic factor, Ki-67 may not be valuable in determining tumor aggressiveness or predicting survival.